Research Examines Efficacy Of Sglt2 Inhibitor As 2ndline Diabetes Therapy | Latest News RSS feed

Research Examines Efficacy Of Sglt2 Inhibitor As 2ndline Diabetes Therapy - Latest News

Merck's Diabetes Pipeline Candidates Are Sure Bets; Only A Matter Of When

Diabetes is a global health problem, and more than 29 million people in the U.S. have diabetes. This article examines the Merck (NYSE ... Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) inh... read more

AstraZeneca to Highlight Scientific Advancements Across Its Diabetes Portfolio at the American Diabetes Association 76 th Scientific Sessions

The studies to be presented evaluate the management of multiple risk factors associated with type 2 diabetes ... SGLT-2 inhibitors, GLP-1 receptor agonists and DPP-4 inhibitors. As a strategic therapy ... read more

Real-world data finds patients feel better on Entresto, says Novartis

At the moment much of the interest in new drug therapies for heart failure lies in the use of antidiabetic drugs and particularly SGLT2 inhibitors such ... in patients who do not have diabetes. “It is ... read more

Looking for another news?

SGLT-2 Inhibitors: A New Mechanism for Glycemic Control

This article provides an overview of the paradigm shift that triggered the development of the SGLT-2 inhibitor class of agents ... this new class of treatment for type 2 diabetes, as well as published ... read more

Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice

... efficacy of SGLT2 inhibition as a valid strategy for the treatment of type 2 diabetes (7 – 19). Although many reports have attested to the efficacy of SGLT2 inhibitors in improving glucose intoler... read more

Triple therapy in type 2 diabetes; a systematic review and network meta-analysis

Methods. A systematic literature review was performed to update the relevant evidence from 2002 to 2014 on triple therapy for type 2 diabetes. A multiple-treatments network meta-analysis was undertake... read more

Biotech and Pharma Update: January 2014

All-Oral, Interferon-Free Therapy for ... glucose co-transporter 2 (SGLT2) inhibitor that blocks the reabsorption of glucose by the kidney, increases glucose excretion, and lowers blood glucose levels ... read more

Buy vTv Therapeutics For Its Novel Alzheimer's And Anti-Diabetic Drug Candidates.

Extensive research has now shown that dysfunction of the GK enzyme may lead to development of type II diabetes. In preclinical studies, drugs targeting the activation of GK enzyme have shown efficacy ... read more

Pharma Stock Roundup: Aerie's Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs

Key announcements this week include the FDA approval of an eye disease drug as well as a diabetes treatment and label expansions ... next-generation oral androgen receptor (“AR”) inhibitor for the tre... read more

Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes

1 Translational Research Institute ... as well as safety and efficacy data, and considering patient convenience and personal choices, it appears that SGLT2 inhibitors would be a reasonable alternative ... read more

When and How to Use U500 (or Other Concentrated) Insulin

It was first introduced into clinical practice in 1952 to address the high insulin requirements of patients with diabetes who had developed ... making addition of an SGLT-2 inhibitor less attractive a... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us